Table 3.
The correlations of CTLA-4 gene expression levels in PBMCs with clinicopathological features in patients with colorectal carcinoma (CRC).
| Characteristics | Total (n = 29) | Low | High | p-Value |
|---|---|---|---|---|
| Gender | ||||
| Female | 11 (37.9%) | 4 (36.4%) | 7 (63.6%) | 0.104 |
| Male | 18 (62.1%) | 2 (11.1%) | 16 (88.9%) | |
| Age | ||||
| ≤60 years | 8 (27.6%) | 3 (37.5%) | 5 (62.5%) | 0.185 |
| >60 years | 21(72.4%) | 3 (14.3%) | 18 (85.7%) | |
| Size | ||||
| ≤50 mm | 20 (69.0%) | 4 (20.0%) | 16 (80.0%) | 0.892 |
| >50 mm | 9 (31.0%) | 2 (22.2%) | 7 (77.8%) | |
| Tumour perforation | ||||
| No | 26 (89.7%) | 6 (23.1%) | 20 (76.9%) | 0.224 |
| With perforation | 3 (10.3%) | 0 (0.0%) | 3 (100.0%) | |
| Site | ||||
| Colon | 18 (62.1%) | 4 (22.2%) | 14 (77.8%) | 0.793 |
| Rectum | 11 (37.9%) | 2 (18.2%) | 9 (81.8%) | |
| Grade | ||||
| Well | 5 (17.2%) | 1 (20.0%) | 4 (80.0%) | 0.355 |
| Moderate | 20 (69.0%) | 5 (25.0%) | 15 (75.0%) | |
| Poor | 4 (13.8%) | 0 (0.0%) | 4 (100.0%) | |
| T stage | ||||
| I or II | 12 (41.40%) | 4 (33.3%) | 8 (66.7%) | 0.160 |
| III or IV | 17 (58.6%) | 2 (11.8%) | 15 (88.2%) | |
| Lymph node status | ||||
| Negative | 17 (58.6%) | 6 (35.3%) | 11 (64.7%) | 0.006 |
| Positive | 12 (41.4%) | 0 (0.0%) | 12 (100.0%) | |
| Distant metastasis | ||||
| Negative | 23 (79.3%) | 6 (26.1%) | 17 (73.9%) | 0.213 |
| Positive | 6 (20.7%) | 0 (0.0%) | 6 (100.0%) | |
| Overall stage | ||||
| I or II | 16 (55.2%) | 6 (37.5%) | 10 (62.5%) | 0.004 |
| III or IV | 13 (44.8%) | 0 (0.0%) | 13 (100.0%) | |
| MSI status | ||||
| Stable | 25 (86.2%) | 4 (16.0%) | 21 (84.0%) | 0.180 |
| High | 4 (13.8%) | 2 (50.0%) | 2 (50.0%) | |
| CTC group | ||||
| Low | 14 (48.3%) | 5 (35.7%) | 9 (64.3%) | 0.046 |
| High | 15 (51.7%) | 1 (6.7%) | 14 (93.3%) |